Nasdaq · CIK 0001108205
CRIS CURIS INC
Insider trading from SEC Form 4. Last filing Apr 1, 2026.
CURIS INC (CRIS) has 28 SEC Form 4 filings on file from 9 insiders, the latest filed on Apr 1, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
1 open-market trade has been scored at CRIS. The newest: Kenneth I Kaitin (director) bought $5,487 of stock on Mar 31, 2026, filed Apr 1, 2026, scored 25 (weak).
Last 90 days
Signals
Open-market buys and sells at CURIS INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 25Weak | Kenneth I Kaitin director buy | $5,487 10,000 shares | +711% | - |
Transactions
Every row filed, 48 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | Kenneth I Kaitin director | POpen-market purchase Common Stock | +10,000 | $0.55 | $5,487 | 11,407 | Apr 1, 2026 |
| Mar 20, 2026 | Marc Rubin director | CConversion Common Stock | +26,667 | - | - | 28,108 | Mar 23, 2026 |
| Mar 20, 2026 | Jonathan B. Zung CDO | CConversion Common Stock | +66,667 | - | - | 66,667 | Mar 23, 2026 |
| Mar 20, 2026 | Ahmed Hamdy MD CMO | CConversion Common Stock | +66,667 | - | - | 66,667 | Mar 23, 2026 |
| Mar 20, 2026 | Diantha Duvall CFO | CConversion Common Stock | +66,666 | - | - | 77,707 | Mar 23, 2026 |
| Mar 20, 2026 | James E Dentzer President & CEO | CConversion Common Stock | +133,333 | - | - | 148,730 | Mar 23, 2026 |
| Mar 20, 2026 | James E Dentzer President & CEO | CConversion Series B Convertible Preferred Stockderivative | -100 | - | - | 0 | Mar 23, 2026 |
| Mar 20, 2026 | Diantha Duvall CFO | CConversion Series B Convertible Preferred Stockderivative | -50 | - | - | 0 | Mar 23, 2026 |
| Mar 20, 2026 | Ahmed Hamdy MD CMO | CConversion Series B Convertible Preferred Stockderivative | -50 | - | - | 0 | Mar 23, 2026 |
| Mar 20, 2026 | Marc Rubin director | CConversion Series B Convertible Preferred Stockderivative | -20 | - | - | 0 | Mar 23, 2026 |
| Mar 20, 2026 | Jonathan B. Zung CDO | CConversion Series B Convertible Preferred Stockderivative | -50 | - | - | 0 | Mar 23, 2026 |
| Mar 17, 2026 | Marc Rubin director | AGrant or award Series B Convertible Preferred Stockderivative | +20 | - | - | 20 | Mar 18, 2026 |
| Mar 17, 2026 | Jonathan B. Zung CDO | AGrant or award Series B Convertible Preferred Stockderivative | +50 | - | - | 50 | Mar 18, 2026 |
| Mar 17, 2026 | James E Dentzer President & CEO | AGrant or award Series B Convertible Preferred Stockderivative | +100 | - | - | 100 | Mar 18, 2026 |
| Mar 17, 2026 | Ahmed Hamdy MD CMO | AGrant or award Series B Convertible Preferred Stockderivative | +50 | - | - | 50 | Mar 18, 2026 |
| Mar 17, 2026 | Diantha Duvall CFO | AGrant or award Series B Convertible Preferred Stockderivative | +50 | - | - | 50 | Mar 18, 2026 |
| Mar 17, 2026 | Jonathan B. Zung CDO | AGrant or award Series A Warrant (right to buy)derivative | +66,667 | - | - | 66,667 | Mar 18, 2026 |
| Mar 17, 2026 | Ahmed Hamdy MD CMO | AGrant or award Series A Warrant (right to buy)derivative | +66,667 | - | - | 66,667 | Mar 18, 2026 |
| Mar 17, 2026 | Diantha Duvall CFO | AGrant or award Series A Warrant (right to buy)derivative | +66,666 | - | - | 66,666 | Mar 18, 2026 |
| Mar 17, 2026 | James E Dentzer President & CEO | AGrant or award Series A Warrant (right to buy)derivative | +133,333 | - | - | 133,333 | Mar 18, 2026 |
| Mar 17, 2026 | Marc Rubin director | AGrant or award Series A Warrant (right to buy)derivative | +26,667 | - | - | 26,667 | Mar 18, 2026 |
| Mar 17, 2026 | James E Dentzer President & CEO | AGrant or award Series B Warrant (right to buy)derivative | +133,333 | - | - | 133,333 | Mar 18, 2026 |
| Mar 17, 2026 | Diantha Duvall CFO | AGrant or award Series B Warrant (right to buy)derivative | +66,666 | - | - | 66,666 | Mar 18, 2026 |
| Mar 17, 2026 | Ahmed Hamdy MD CMO | AGrant or award Series B Warrant (right to buy)derivative | +66,667 | - | - | 66,667 | Mar 18, 2026 |
| Mar 17, 2026 | Marc Rubin director | AGrant or award Series B Warrant (right to buy)derivative | +26,667 | - | - | 26,667 | Mar 18, 2026 |
| Mar 17, 2026 | Jonathan B. Zung CDO | AGrant or award Series B Warrant (right to buy)derivative | +66,667 | - | - | 66,667 | Mar 18, 2026 |
| Mar 17, 2026 | Diantha Duvall CFO | AGrant or award Series C Warrant (right to buy)derivative | +66,666 | - | - | 66,666 | Mar 18, 2026 |
| Mar 17, 2026 | Marc Rubin director | AGrant or award Series C Warrant (right to buy)derivative | +26,667 | - | - | 26,667 | Mar 18, 2026 |
| Mar 17, 2026 | Ahmed Hamdy MD CMO | AGrant or award Series C Warrant (right to buy)derivative | +66,667 | - | - | 66,667 | Mar 18, 2026 |
| Mar 17, 2026 | Jonathan B. Zung CDO | AGrant or award Series C Warrant (right to buy)derivative | +66,667 | - | - | 66,667 | Mar 18, 2026 |
| Mar 17, 2026 | James E Dentzer President & CEO | AGrant or award Series C Warrant (right to buy)derivative | +133,333 | - | - | 133,333 | Mar 18, 2026 |
| May 20, 2025 | Jonathan B. Zung CDO | AGrant or award Employee stock option (right to buy)derivative | +135,000 | $3.13 | $423k | 135,000 | May 22, 2025 |
| May 20, 2025 | James E Dentzer President & CEO | AGrant or award Employee stock option (right to buy)derivative | +360,000 | $3.13 | $1.1M | 360,000 | May 22, 2025 |
| May 20, 2025 | John Hohneker director | AGrant or award Non Qualified Stock Optionderivative | +14,400 | $3.13 | $45k | 14,400 | May 22, 2025 |
| May 20, 2025 | Martyn D Greenacre director | AGrant or award Non Qualified Stock Optionderivative | +14,400 | $3.13 | $45k | 14,400 | May 22, 2025 |
| May 20, 2025 | Marc Rubin director | AGrant or award Non Qualified Stock Optionderivative | +14,400 | $3.13 | $45k | 14,400 | May 22, 2025 |
| May 20, 2025 | Diantha Duvall CFO | AGrant or award Employee stock option (right to buy)derivative | +135,000 | $3.13 | $423k | 135,000 | May 22, 2025 |
| May 20, 2025 | Kenneth I Kaitin director | AGrant or award Non Qualified Stock Optionderivative | +14,400 | $3.13 | $45k | 14,400 | May 22, 2025 |
| May 20, 2025 | Anne Elizabeth Borgman director | AGrant or award Non Qualified Stock Optionderivative | +14,400 | $3.13 | $45k | 14,400 | May 22, 2025 |
| May 1, 2025 | Ahmed Hamdy MD CMO | AGrant or award Employee stock option (right to buy)derivative | +200,000 | $2.48 | $496k | 200,000 | May 5, 2025 |
| Jan 28, 2025 | Anne Elizabeth Borgman director | AGrant or award Non Qualified Stock Optionderivative | +1,600 | $3.13 | $5,008 | 1,600 | Jan 30, 2025 |
| Jan 28, 2025 | Martyn D Greenacre director | AGrant or award Non Qualified Stock Optionderivative | +1,600 | $3.13 | $5,008 | 1,600 | Jan 30, 2025 |
| Jan 28, 2025 | John Hohneker director | AGrant or award Non Qualified Stock Optionderivative | +1,600 | $3.13 | $5,008 | 1,600 | Jan 30, 2025 |
| Jan 28, 2025 | Marc Rubin director | AGrant or award Non Qualified Stock Optionderivative | +1,600 | $3.13 | $5,008 | 1,600 | Jan 30, 2025 |
| Jan 28, 2025 | Kenneth I Kaitin director | AGrant or award Non Qualified Stock Optionderivative | +1,600 | $3.13 | $5,008 | 1,600 | Jan 30, 2025 |
| Jan 28, 2025 | Jonathan B. Zung CDO | AGrant or award Employee stock option (right to buy)derivative | +15,000 | $3.13 | $47k | 15,000 | Jan 30, 2025 |
| Jan 28, 2025 | James E Dentzer President & CEO | AGrant or award Employee stock option (right to buy)derivative | +40,000 | $3.13 | $125k | 40,000 | Jan 30, 2025 |
| Jan 28, 2025 | Diantha Duvall CFO | AGrant or award Employee stock option (right to buy)derivative | +15,000 | $3.13 | $47k | 15,000 | Jan 30, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Anne Elizabeth Borgmandirector, officer
- James E DentzerPresident & CEO
- Diantha DuvallCFO
- Martyn D Greenacredirector
- Ahmed Hamdy MDCMO
- John Hohnekerdirector
- Kenneth I Kaitindirector
- Marc Rubindirector
- Jonathan B. ZungCDO
Questions about CRIS
Answered from the filings on this page, as of the latest one.
Are insiders buying CRIS?
No. In the last 90 days no insider at CURIS INC bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade CRIS on the open market?
Kenneth I Kaitin (director) bought $5,487 of CRIS on Mar 31, 2026 and filed the Form 4 on Apr 1, 2026. InsiderTell scored 25 (weak).
How many insiders file Form 4 at CURIS INC?
9 people have filed a Form 4 at CURIS INC, among them Anne Elizabeth Borgman (director and officer), James E Dentzer (President & CEO), Diantha Duvall (CFO). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.